CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) and Siga Technologies (NASDAQ:SIGA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability.
Insider and Institutional Ownership
22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 55.4% of Siga Technologies shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of Siga Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares CASI Pharmaceuticals and Siga Technologies”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CASI Pharmaceuticals | $26.85 million | 0.10 | -$39.26 million | ($3.01) | -0.07 |
| Siga Technologies | $94.57 million | 4.01 | $23.28 million | $0.31 | 17.10 |
Siga Technologies has higher revenue and earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations for CASI Pharmaceuticals and Siga Technologies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CASI Pharmaceuticals | 1 | 0 | 1 | 0 | 2.00 |
| Siga Technologies | 0 | 1 | 0 | 0 | 2.00 |
CASI Pharmaceuticals presently has a consensus target price of $4.00, suggesting a potential upside of 1,827.71%. Given CASI Pharmaceuticals’ higher possible upside, equities analysts clearly believe CASI Pharmaceuticals is more favorable than Siga Technologies.
Volatility and Risk
CASI Pharmaceuticals has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Siga Technologies has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.
Profitability
This table compares CASI Pharmaceuticals and Siga Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CASI Pharmaceuticals | -183.93% | N/A | -131.54% |
| Siga Technologies | 24.61% | 11.25% | 9.98% |
Summary
Siga Technologies beats CASI Pharmaceuticals on 10 of the 13 factors compared between the two stocks.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
About Siga Technologies
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
